Advertisement

Clinical and Translational Oncology

, Volume 20, Issue 8, pp 1004–1010 | Cite as

Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy

  • S. García-Barreras
  • F. Rozet
  • I. Nunes-Silva
  • V. Srougi
  • R. Sanchez-Salas
  • E. Barret
  • M. Galiano
  • X. Cathelineau
Research Article
  • 110 Downloads

Abstract

Purpose

To evaluate predictive factors associated with detectable prostate-specific antigen (PSA) and describe clinical recurrence (CR) and cancer-specific mortality (CSM) after robot-assisted radical prostatectomy (RARP).

Methods

The study included 2500 patients who were treated with RARP at a single institution between 2000 and 2016. All patients had clinically localized PCa. Patients were divided into two groups according to PSA value at 6 weeks after surgery: undetectable (n = 2271; PSA < 0.1 ng/dl) and persistently elevated (n = 229; PSA ≥ 0.1 ng/dl). The association between various covariates and: (1) detectable PSA and (2) CR was evaluated. Kaplan–Meier analyses estimated CR and CSM rates according to PSA persistence.

Results

Inside the group of detectable PSA, 146 men (63.75%) received adjuvant treatments, 44 patients (19.21%) salvages therapies and 38 men (16.5%) experienced CR. Factors associated with aggressive disease predicted PSA persistence. Within patients with detectable PSA, pathologic stage ≥ pT3a (HR 2.71; p < 0.029) and to received adjuvant androgen deprivation therapy (ADT) due to bad prognosis tumors (HR 13.36; p < 0.001) were associated with CR. Overall 14 (0.56%) died of PCa. 5 and 10-year CSM rates were higher for patients with CR (9.6 and 23.7%, p < 0.001), and Gleason ≥ 8 (5.7 and 6.9%, p = 0.003).

Conclusions

A detectable PSA is affected by factors associated with aggressive prostate cancer. Within men with persistent PSA, those with higher pathologic stage and who received adjuvant ADT are more likely to have CR. Patients with CR, Gleason ≥ 8, and those who received adjuvant ADT must have a close monitoring due to the high rate of mortality.

Keywords

Prostate cancer Minimal-invasive radical prostatectomy Detectable prostate-specific antigen 

Notes

Author contributions

SG-B: project development, data collection and manuscript writing. FR: project development. IN-S: statistical analysis. VS: data collection. RS-S: data collection. EB: editing. MG: editing. XC: project development and manuscript writing.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

CEPAR: Comité d’Evaluation des Protocoles et d’Aide à la Recherche (Protocol Evaluation Committee and for Research Assistance) committee approved the study.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

12094_2017_1812_MOESM1_ESM.tiff (29.5 mb)
Supplementary material 1 (TIFF 30242 kb)
12094_2017_1812_MOESM2_ESM.tiff (29.5 mb)
Supplementary material 2 (TIFF 30242 kb)
12094_2017_1812_MOESM3_ESM.pdf (397 kb)
Supplementary material 3 (PDF 397 kb)
12094_2017_1812_MOESM4_ESM.pdf (26 kb)
Supplementary material 4 (PDF 25 kb)
12094_2017_1812_MOESM5_ESM.pdf (27 kb)
Supplementary material 5 (PDF 27 kb)

References

  1. 1.
    Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer. 2013;8:S0959–8049.Google Scholar
  2. 2.
    Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: national Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010;102:950–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290–314.CrossRefPubMedGoogle Scholar
  4. 4.
    Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977.CrossRefPubMedGoogle Scholar
  5. 5.
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591.CrossRefPubMedGoogle Scholar
  6. 6.
    Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol. 2009;181:601.CrossRefPubMedGoogle Scholar
  7. 7.
    Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparatives studies. Eur Urol. 2009;55:1037–63.CrossRefPubMedGoogle Scholar
  8. 8.
    Coelho RF, Rocco B, Patel MB. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol. 2010;24:2003–15.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Suardi N, Ficarra V, Willemsen P, De Wil P, Gallina A, De Naeyer G, Schatteman P, Montorsi F, Carpentier P, Mottrie A. Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years. Urology. 2012;79:133–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Sooriakumaran P, Haendler L, Nyberg T, Gronberg H, Nilsson A, Carlsson S, Hosseini A, Adding C, Jonsson M, Ploumidis A, Egevad L, Steineck G, Wiklund P. Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. Eur Urol. 2012;62:768–74.CrossRefPubMedGoogle Scholar
  11. 11.
    Liss MA, Lusch A, Morales B, Beheshti N, Skarecky D, Narula N, Osann K, Ahlering TE. Robot-assisted radical prostatectomy: 5-year oncological and biochemical outcomes. J Urol. 2012;188:2205–10.CrossRefPubMedGoogle Scholar
  12. 12.
    De Boo L, Pintilie M, Yip P, Baniel J, Fleshner N, Margel D. Time from first detectable PSA following radical prostatectomy to biochemical recurrence: a competing risk analysis. Can Urol Assoc J. 2015;9:E14–21.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Audenet F, Seringe E, Drouin SJ, Comperat E, Cussenot O, Bitker MO, Rouprêt M. Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. World J Urol. 2012;30:239–44.CrossRefPubMedGoogle Scholar
  14. 14.
    Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Definition and preoperative predictors of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. BJU Int. 2009;105:1541–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate specific antigen level after radical prostatectomy. Eur Urol. 2010;57:622–30.CrossRefPubMedGoogle Scholar
  16. 16.
    Kumar A, Samavedi S, Mouraviev V, Bates AS, Coelho RF, Rocco B, et al. Predictive factor and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy. J Robot Surg. 2017;11(1):37–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell’Oglio P, Schiavina R, Montorsi F, Briganti A. The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients. Eur Urol. 2016;69:1142–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 1994;152:1358–68.CrossRefPubMedGoogle Scholar
  19. 19.
    Freedland SJ, Humphreys EB, Mangold LA, Eisenberg M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–9.CrossRefPubMedGoogle Scholar
  20. 20.
    D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate specific antigen failure. J Clin Oncol. 2005;23:4975–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Rogers CG, Khan MA, Miller MC. Natural history of disease progression in patients who fail to achieve an undetectable prostate specific antigen level after undergoing radical prostatectomy. Cancer. 2004;101:2549–56.CrossRefPubMedGoogle Scholar
  22. 22.
    Naselli A, Introini C, Andreatta R, Spina B, Truini M, Puppo P. Prognostic factors of persistently detectable PSA after radical prostatectomy. Int J Urol. 2009;16:82–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ. Metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol. 2016;34:3864–71.CrossRefPubMedGoogle Scholar
  24. 24.
    Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Inmediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol. 2008;54:344–52.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  1. 1.Department of Urology, Institut Mutualiste MontsourisUniversité Paris-DescartesParis Cedex 14France

Personalised recommendations